Adicet Bio, Inc.
ACET · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.05 | 0.19 | 0.13 | -0.35 |
| FCF Yield | -48.02% | -39.11% | -28.72% | -17.13% |
| EV / EBITDA | -1.12 | -1.90 | -1.67 | -1.51 |
| Quality | ||||
| ROIC | -21.76% | -16.81% | -15.07% | -14.42% |
| Gross Margin | 0.00% | 0.00% | 50.00% | 0.00% |
| Cash Conversion Ratio | 0.83 | 0.85 | 0.90 | 0.84 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 0.78% | -10.76% | -8.35% | 5.55% |
| Safety | ||||
| Net Debt / EBITDA | 0.60 | 0.40 | 1.45 | 3.02 |
| Interest Coverage | 0.00 | 0.00 | -30,743.00 | -33,153.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -185.18 | -235.87 | 0.00 | -141.33 |